Quantitative Translation of the Cancer Genome to Proteome

Preclinical Evaluation and Development of New Therapeutic Strategies in Multiple Myeloma

Multiple myeloma, a malignancy of plasma cells, is the second most common hematoligic malignancy in the United States and currently has no known cure. While the development of new therapeutics over the past decade has significantly extended lifespan in this disease, there is still significant work left to do for patients. The Multiple Myeloma Translational Initiative Laboratory, within our group, uses a number of in vitro and in vivo models of myeloma to evaluate the efficacy of promising new therapeutic strategies in myeloma. We also aim to use basic science and screening strategies to identify new drug targets and diagnostic approaches toward this disease.